Biofabrication of vascularized human organs
Building a human-sized, perfusable, functioning organ - kidney, liver or heart - from a patient's own or banked cells.
State of the art
ARPA-H PRINT awarded teams in January 2026 (Wake Forest vascularized renal tissue, Wyss clinical-scale liver tissue, among others) to attempt what the agency states has not been done - printing a human-sized functional organ.
- Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
- Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
- Cell demand of 10^10-10^11 per organ exceeds current manufacturing
- Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
Who’s working on it
- ARPA-H PRINT ↗Program
Awarded five teams up to 176.8 million dollars over five years in January 2026 to attempt what the agency says has not been done, a human-sized functional printed organ
- Anthony AtalaResearcherWake Forest Institute for Regenerative Medicine
Principal investigator of the award of up to 24.8 million dollars announced January 2026 to produce clinical-grade vascularised renal tissue
- Wyss InstituteAcademic lab
PRINT awardee engineering universal clinical-scale liver tissue from adult stem cells as an implantable therapy
- Carnegie Mellon UniversityAcademic lab
PRINT awardee building a cost-effective immune-silent bioprinted liver for acute liver failure, targeting first-in-human within five years
- UT Southwestern Medical CenterAcademic lab
PRINT awardee developing a transplant-ready liver with reconnected blood vessels and a bile duct system, the mechanical-integration problem nobody has solved
- United TherapeuticsCompany
The only established company industrialising manufactured transplantable organs at scale, through gene-edited pigs and dedicated organ manufacturing facilities
- PrintBioStartup
Commercial partner in the federal kidney bioprinting programme, working on print-and-perfuse hardware rather than therapeutics
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| engineering | Organ-scale print-and-perfuse platforms with integrated bioreactor maturation, measured against transplant function endpoints in large animals | $$$ $100M – $1B |
| research | Maturation protocols (flow, electrical, metabolic conditioning) that move printed tissue from fetal to adult function | $$$ $100M – $1B |